Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial

Q J Med. 1994 Feb;87(2):75-81.

Abstract

Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • AIDS-Related Opportunistic Infections / immunology
  • Adolescent
  • Adult
  • Aged
  • Amphotericin B / administration & dosage*
  • Amphotericin B / adverse effects
  • Animals
  • Child
  • Child, Preschool
  • Drug Carriers
  • Female
  • HIV / immunology
  • Humans
  • Immune Tolerance
  • Immunocompromised Host
  • Infant
  • Leishmania infantum*
  • Leishmaniasis, Visceral / drug therapy*
  • Leishmaniasis, Visceral / immunology
  • Liposomes
  • Male
  • Middle Aged

Substances

  • Drug Carriers
  • Liposomes
  • Amphotericin B